Key result
Intramuscular injection of rAAV in macaques appeared safe with no tissue abnormalities at 8 to 18 months, despite transient viremia and persistence of rAAV sequences in PBMC, lymph nodes, and liver.
Why the study?
Is intramuscular injection of recombinant adeno-associated virus safe and what is its dissemination profile in macaques?
Is intramuscular injection of recombinant adeno-associated virus safe and what is its dissemination profile in macaques?
Intramuscular rAAV injection in macaques appears safe over 8-18 months, despite transient viremia and long-term persistence of viral sequences in certain tissues.
No takes yet. Share an insight, caveat, or question.
Supports further rAAV vector development in primates; leaves open human safety and biodistribution questions.
Favre et al. (2001) studied this question. Recombinant adeno-associated virus (rAAV) injection was evaluated on Dissemination, shedding, long-term persistence in distant organs, and tissue abnormalities. Intramuscular injection of rAAV in macaques appeared safe with no tissue abnormalities at 8 to 18 months, despite transient viremia and persistence of rAAV sequences in PBMC, lymph nodes, and liver.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: